Process validation ensures manufacturing consistency, reduces deviations, prevents rework, improves resource utilization, and facilitates production scale-up. As a direct result, it accelerates time to market.

For many years, process validation has been viewed by management teams as a costly formality, a box to tick to comply with regulations. A kind of “necessary evil” more closely associated with regulatory compliance than with real business value.

However, this perception is becoming outdated. Today, it is widely understood that validation is not just a regulatory requirement; it is a strategic driver that enhances efficiency, quality and long-term profitability. When approached with a business-oriented, data-driven mindset, validation ceases to be a bureaucratic exercise and becomes a powerful tool for continuous improvement and sustainable growth.

Beyond Compliance: Process validation as a Strategic Investment

Traditionally, validation efforts have focused on “meeting the guidelines” (FDA, EMA, ICH Q7, among others). In practice, however, when validation is done properly, it significantly improves the overall operational health of an organization.

A clear example can be found when analyzing the Cost of Poor Quality (COPQ). In the pharmaceutical industry, COPQ can represent between 25% and 40% of revenue, far above the 4–8% seen in high-precision industries such as aerospace. This gap highlights the true impact of reactive quality management compared to a proactive approach built on validation and control.

Every deviation, failed batch or unsuccessful audit costs money, time, and reputation. Validation, on the other hand, prevents issues, anticipates risks and optimizes processes. In an increasingly competitive environment, the real cost is not validation itself, but failing to do it properly.

The question management should be asking is no longer “How much does validation cost?” but rather “How much does poor quality cost us?”

Process validation as a Catalyst for Growth and Agility

From a growth perspective, validation plays a key role in accelerating time to market. By clearly defining Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs), companies gain a deep understanding of both product and process behavior.

This knowledge is essential during technology transfer and industrial scale-up. Identifying critical parameters at early development stages can dramatically reduce the transition time from pilot scale to full-scale production.

In practical terms, a robust validation strategy delivers:

• More efficient product launches: validated processes minimize issues during tech transfer and early manufacturing.

• Faster global expansion: validation data supports smoother and quicker local regulatory approvals.

• Continuous optimization: validation outcomes provide actionable insights for ongoing, data-driven process improvements.

Efficiency, Speed, and Risk Reduction

As discussed, strong validation directly translates into operational efficiency and risk reduction. These benefits are often reflected in a well-known manufacturing KPI: Overall Equipment Effectiveness (OEE). A well-validated process reduces variability, increases stability and improves overall productivity.

Even small improvements in yield or downtime can generate substantial annual savings in high-volume manufacturing environments.

Robust validation also protects against regulatory risk. Many of the most serious FDA findings, such as inspection observations or product recalls, stem from inadequately validated processes.

The numbers are striking: the cost of regulatory non-compliance can be three to ten times higher than the cost of proper validation. On top of that come indirect costs such as loss of trust, reputational damage and market disruption.

Cost Reduction and Resource Optimization

Another major benefit of well-planned validation is cost reduction. A validated process leads to fewer non-conformities, fewer deviations, less rework, and reduced material waste. This means fewer investigations, fewer unproductive labor hours and more predictable manufacturing output.

From a financial standpoint, validation should not be seen as an expense, but as an investment.

Furthermore, robust validation enables better resource utilization, improved inventory planning, and a stronger supply chain. All of this contributes to more stable, predictable and profitable operations.

The Consequences of Weak Validation

Despite being a regulatory requirement, many organizations still make fundamental mistakes in their validation approach. The most common pitfalls include:

• Incomplete protocols that fail to cover critical parameters.

• Insufficient or inconsistent documentation.

• Failure to consider worst-case scenarios.

• Inadequate or missing risk assessments.

These shortcomings open the door to regulatory observations, major deviations, and in some cases, sanctions.

In 2024 alone, the FDA issued 85 observations to medical device companies related to process validation issues, compared to 39 in pharmaceutical companies. This discrepancy suggests uneven maturity levels in validation practices across industries.

The financial consequences can be severe: remediation costs, legal support, delayed launches, lost market share and long-term reputational damage. Weak validation puts product quality, compliance and financial sustainability at risk.

Elevating Validation to a Strategic Level

Process validation should not be treated as a quality assurance afterthought, but as a strategic pillar of business competitiveness.

Key recommendations for leadership include:

1. Integrate validation into business strategy, aligning validation timelines with product development and market entry goals.

2. Invest in people and tools, ensuring teams are properly trained and supported by suitable digital systems.

3. Promote a cross-functional quality culture, where manufacturing, engineering, quality, and regulatory teams work collaboratively.

4. Leverage validation data to drive continuous improvement and anticipate issues before they arise.

5. Validate under demanding conditions, not just to meet minimum regulatory requirements, but to ensure true robustness and reproducibility.

Conclusion

When companies stop viewing validation as a bureaucratic requirement and start treating it as a strategic tool, the benefits are clear. In an environment where speed, quality and reliability are critical, robust process validation is not a cost, it is a competitive advantage.

Because in the end, the real question is not how much validation costs, but how much it costs not to do it properly.

About 53Biologics:

53Biologics is a Spanish CDMO specialized in decoding biologics production, from DNA to proteins. The company provide services from preclinical development to GMP manufacturing, supporting their clients in getting their biological products to market as quickly as possible.

For more information or to speak with one of our experts email us at info@53biologics.com